Nymox Pharmaceutical has announced the Immunogenicity results for its drug candidate NX-1207 BPH Program, which has not shown any evidence of eliciting an immune reaction in men treated with intraprostatic injections of the drug. NX-1207 ...
Tags: Nymox Pharmaceutical, Immunogenicity results, NX-1207 BPH Program